PROM1 and cancer: In a phase I clinical study evaluating CD133 CAR-T cells (NCT02541370), a therapy targeting the cancer stem cell marker CD133, 23 patients, including 7 with stage IV PADCs (grade 2 or 3), were enrolled [89].